1

Estimating hepatitis B virus cccDNA persistence in chronic infection

Katrina A. Lythgoe[1,2], Sheila F. Lumley[3,4], Lorenzo Pellis[5], Jane A. McKeating[6+] and Philippa C. Matthews[3,4,7+]

[1] Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF.
[2] Department of Zoology, University of Oxford, Medawar Building, South Parks Road, Oxford OX1 3SY.
[3] Nuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford OX1 3SY.
[4] Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU.
[5] Department of Mathematics, University of Manchester, Manchester, UK
[6] Nuffield Department of Medicine Research Building, University of Oxford, Oxford, OX3 7LF.
[7] NIHR Biomedical Research Centre, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU.

[+] Denotes equal contribution

Corresponding author: Katrina Lythgoe, Email: katrina.lythgoe@bdi.ox.ac.uk

Running header: cccDNA persistence during HBV infection

Key words: hepatitis B virus, cccDNA, persistence, evolution, dynamics, reservoir, modelling

Author contributions:
KAL: Conceptualisation, Formal analysis, Funding acquisition, Methodology, Writing – original draft, Writing – Review & Editing
SFL: Formal analysis, Investigation, Writing – original draft
LP: Methodology, Writing – Review & Editing
JAM: Conceptualisation, Writing – Review & Editing
PCM: Conceptualisation, Writing – Review & Editing

Abstract

Hepatitis B virus (HBV) infection is a major global health problem with over 240 million

infected individuals at risk of developing progressive liver disease and hepatocellular

carcinoma. HBV is an enveloped DNA virus that establishes its genome as an episomal,

covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes.

Currently available standard-of-care treatments for chronic hepatitis B (CHB) include

nucleos(t)ide analogues (NA) that suppress HBV replication but do not target the

cccDNA and hence rarely cure infection. There is considerable interest in determining

the lifespan of cccDNA molecules to design and evaluate new curative treatments. We

took a novel approach to this problem by developing a new mathematical framework

to model changes in evolutionary rates during infection which, combined with

previously determined within-host evolutionary rates of HBV, we used to determine

the lifespan of cccDNA. We estimate that during HBe-antigen positive (HBeAg[POS])

infection the cccDNA lifespan is 61 (36-236) days, whereas during the HBeAg[NEG] phase

of infection it is only 26 (16-81) days. We found that cccDNA replicative capacity

declined by an order of magnitude between HBeAg[POS] and HBeAg[NEG] phases of

infection. Our estimated lifespan of cccDNA is too short to explain the long durations

of chronic infection observed in patients on NA treatment, suggesting that either a

sub-population of long-lived hepatocytes harbouring cccDNA molecules persists

during therapy, or that NA therapy does not suppress all viral replication. These results

provide a greater understanding of the biology of the cccDNA reservoir and can aid

the development of new curative therapeutic strategies for treating CHB.

Author Summary

Nearly one million people die each year due to hepatitis B virus (HBV) related diseases.

Although antiviral treatments for HBV exist, cure is rare and treatment is typically life-

long, reflecting the persistence of episomal copies of the viral DNA (cccDNA) in the

liver. Our knowledge of the cccDNA reservoir in chronic hepatitis B (CHB) is limited.

HBV has a high mutation rate and the key determinants of cccDNA dynamics can be

inferred by examining the rate of viral evolution. Combining a mathematical model

and known rates of HBV evolution we estimate the cccDNA lifespan during different

phases of CHB. Our results provide important insights into the dynamics of the HBV

reservoir that will inform the design of future treatment interventions.

INTRODUCTION

Hepatitis B Virus (HBV) is a global health problem, with more than 240 million chronically infected individuals at risk of developing liver fibrosis, cirrhosis, and hepatocellular carcinoma [1]. HBV is the prototypic member of the *hepadnaviruses*, a family of small, enveloped hepatotropic viruses with a partially double-stranded relaxed circular DNA (rcDNA) genome that replicates via reverse transcription of pregenomic RNA (pgRNA). Following the infection of hepatocytes, the rcDNA genome is imported to the nucleus and converted to covalently closed circular DNA (cccDNA), that provides the transcriptional template for pregenomic and subgenomic RNAs. Newly synthesized pgRNA is assembled into nucleocapsids that undergo reverse transcription to generate rcDNA, which is subsequently enveloped and released as infectious virions. Alternatively, capsids can be redirected to the nucleus to replenish and maintain the episomal pool of cccDNA and this intracellular amplification pathway, together with the long half-life of cccDNA, contributes to viral persistence [2,3].

Chronic hepatitis B (CHB) is usually treated with nucleos(t)ide analogues (NAs) that inhibit the reverse transcription of pgRNA to rcDNA. However, these therapies do not directly target the cccDNA reservoir [4] and viremia rebounds once treatment is stopped, even when peripheral levels of viral DNA have remained undetectable for months or years [5]. There is a growing impetus to identify curative therapies for HBV [6]. Despite its central role in the HBV life cycle, our understanding of the viral and host factors that regulate cccDNA abundance and half-life is limited[7]. cccDNA half-life can be defined as the time for the number of copies in the liver to reduce by half and will depend on a number of factors, including cccDNA 'lifespan' (the time an

individual cccDNA molecule persists) and the genesis of new cccDNA via extra-cellular

virus infection or intra-cellular amplification [8,9] (Fig.1a). A recent *in vitro* study

reported a 40 day half-life of HBV cccDNA in infected HepG2-NTCP cells [2], with an

estimated lifespan of 58 days. However, the cccDNA lifespan in the human liver is

unknown.

The lifespan of cccDNA molecules most likely changes over the course of CHB,

influenced by host and viral factors [10], including the rate of hepatocyte proliferation

[11,12]. The natural history of CHB is often classified by four clinical or virological

phases of infection and/or hepatitis (according to European Association for the Study

of the Liver 2017[13]). However, it is increasingly recognised that this description fails

to capture the diversity of viral replication in the liver and misleadingly suggests a

linear progression over time from one phase to the next. To avoid difficulties

associated with this rigid phenotypic structure of disease, and to focus on viral

dynamics rather than disease pathology, we instead consider two states: HBeAg^POS

that is associated with high peripheral HBV DNA levels (viral load - VL), and HBeAg^NEG,

which is associated with lower VLs [14]. Early in infection cccDNA is transcriptionally

active and translation of pre-core/pgRNA results in detectable levels of hepatitis B e

antigen (HBeAg) in the periphery, associated with high VL [15]. In later stages of

infection after HBeAg seroconversion there is a loss of HBeAg that associates with

more efficient immune targeting of infected cells [16], leading to a reduction in VL and

a shortening of cccDNA lifespan. The higher hepatocyte death rates during HBeAg^NEG

CHB infection will induce hepatocyte proliferation [15]. The extent to which cccDNA is

lost during hepatocyte mitosis is uncertain [9], but unless all cccDNA episomes survive

mitosis, the increased proliferation rate of infected cells will shorten the average

lifespan of cccDNA [12,17,18].

Double-stranded DNA viruses typically have low mutation rates, but since rcDNA is

generated via error prone reverse transcription in the *hepadnaviridae*, they have

higher mutation rates than other DNA viruses (Fig 1A) [19]. The estimated mutation

rate for avian hepadnavirus is $2x10^{-5}$ substitutions per site per infected cell (s/s/c) [20],

and an upper limit of $8.7x10^{-5}$ s/s/c has been estimated for HBV [21], similar to

estimates for RNA retroviruses [22]. The evolutionary rate measures how quickly

mutations become fixed in a population over a period of time [23]. Strikingly, the

evolutionary rate of HBV is much lower than for RNA viruses with similar mutation

rates [24–26]. Different mechanisms could explain this observation, including the

biological constraint of multiple overlapping reading frames in the HBV genome [24],

limited viral population size in the liver, or long cccDNA lifespan [24,25]. Both

evolutionary constraint and population size should only influence the rate of evolution

of variants that experience selection [27]. For neutral or near neutral mutations, the

long cccDNA lifespan provides the simplest explanation for the low evolutionary rate

of HBV [25].

We propose the within-host evolutionary rate of HBV can be used to estimate cccDNA

lifespan and the replicative capacity (a combined measure of extra-cellular viral

production and intra-cellular amplification) of the virus. We developed a novel

mathematical model that uses published HBV mutation and evolutionary rates

[20,24,26], to infer the lifespan and replicative capacity of cccDNA during different

phases of CHB. Although we use our model to consider the neutral rate of evolution,

it is essentially an ecological model, in that we do not assume any viral phenotypic

evolution. To the best of our knowledge, these are the first estimates of cccDNA

lifespan in treatment naïve subjects and provide important insights into the HBV

reservoir that will be valuable for the design and evaluation of future treatment

interventions.

Fig 1: **Summary of the HBV life cycle, mathematical model, and estimated cccDNA**

lifespan. A: Simplified HBV replication cycle. A virus particle containing relaxed circular

DNA (rcDNA) enters a hepatocyte (blue circle) and is uncoated. The rcDNA is

transported to the nucleus (purple circle) and repaired to generate cccDNA. This

cccDNA is the transcriptional template for all viral RNAs, including pre-genomic

(pgRNA), which is transported to the cytoplasm, encapsidated, and converted into

rcDNA by error-prone reverse transcription. The encapsidated rcDNA can be

transported back into the nucleus to form more cccDNA (intra-cellular amplification),

or enveloped and released as virions that can infect hepatocytes (extra-cellular

amplification). **B**: Structure of the mathematical model. This is a single compartment

model representing the burden of cccDNA in the liver, Y, over the course of infection.

The cccDNA burden can increase due to amplification (intra- and extra-cellular), where

b is a measure of the within-host replicative capacity of cccDNA. cccDNA can be

cleared from the liver due to natural cell death, at rate d per day, cytolytic immune

responses at rate δ per day, and non-cytolytic immune responses at rate c per day.

Proliferation can also result in loss of cccDNA at rate $(1-q)(d+\delta Y)$, where q is probability

that an individual cccDNA survives mitosis. **C**: Representation of the model dynamics

and key results, where the numbers give the most likely values inferred by fitting the

mutation and evolutionary rates to the model. The darker the colours on the figure

the higher the cccDNA burden (reds) and the stronger the immune response (blues).

 RESULTS

We developed a mathematical model describing the number of cccDNA molecules in

the liver that is independent of infected cell frequency, and accounts for intra- and

extra-cellular cccDNA amplification and loss of cccDNA during hepatocyte mitosis (Fig

1B and Methods, Eqs 1 and 2). Using this model we derived expressions for the viral

generation time, defined as the typical time for one cccDNA molecule to generate

another cccDNA molecule at time t since infection, $g(t)$ (Eq 5), and the neutral rate of

evolution at time $S(t)$ (Eq 6). At equilibrium, we show that the lifespan of cccDNA, L_E,

is equal to the virus generation time, g_E, which is given by the neutral mutation rate

divided by the neutral rate of evolution, μ/S_E (Eq 8). The notation used throughout is

given in Table 1.

Table 1: Notation used to describe the model

$N(t), N_E$	Number of cccDNA molecules at time t since infection and at equilibrium
K	Maximum possible number of cccDNA molecules
$Y(t), Y_E$	cccDNA burden in the liver at time t since infection and at equilibrium, expressed as a proportion of the maximum possible number of cccDNA, $Y(t)=N(t)/K$, $Y_E= N_E/K$
$\rho(t)$	Per capita proliferation rate of cccDNA at time t since infection
$g(t)$, g_E, $g_{Y<<1}$	Generation time of cccDNA at time t since infection, at equilibrium, and when few cells are infected
$S(t), S_E$	Neutral rate of evolution at time t since infection and at equilibrium

L_E, $L_{Y\ll1}$	Life span of cccDNA molecules at equilibrium and when few cells are infected
β	Per capita replicative capacity, defined as the per capita growth rate of cccDNA when few cells are infected and in the absence of infected cell death or loss of cccDNA due to non-cytolytic immune responses.
R_0	The basic reproductive number of cccDNA (the number of cccDNA molecules a single cccDNA produces in its lifetime in an otherwise uninfected population of hepatocytes)
$b=\beta K$	Replicative capacity of cccDNA (a rescaled measure of the per capita replicative capacity)
d	Per capita natural death rate of hepatocytes
δ	Per capita additional death rate of infected hepatocytes due to cytolytic immune responses
c	Per capita loss rate of cccDNA due to non-cytolytic immune responses
q	Probability that a cccDNA molecule survives mitosis
μ	Mutation rate of cccDNA (substitutions per site per reproduction)

[+] Throughout we use days as the time unit and all rates are per day.

Lifespan of cccDNA

From the published estimates for the mutation [20] and evolutionary rates of HBV

[24,26], we inferred the probability distributions for cccDNA lifespan during HBeAg[POS]

and HBeAg[NEG] phases of CHB using Eq 8. The predicted lifespan of cccDNA during

HBeAg[POS] infection, and when VLs are high and stable, is 61 days (5th-95th percentiles

36-236 days; Fig 2, orange line). In contrast, during HBeAg[NEG] infection the lifespan of

cccDNA is estimated at only 26 days (16-81 days; Fig 2, blue line).

The shorter lifespan of cccDNA during HBeAg^{NEG} compared to HBeAg^{POS} infection can

be explained by higher rates of cccDNA clearance (Eq 9). This may reflect changes in

the immune environment due to HBe-antigen seroconversion that is associated with

increased cytolytic and non-cytolytic immune responses (δ and c respectively).

Increased host immune responses during HBeAg^{NEG} infection could push the basic

reproduction number, R_0, of cccDNA below one (Eq 3) due to the higher clearance

rates of cccDNA molecules, and also due to reduced replicative capacity, b, of cccDNA.

If R_0<1, the number of cccDNA will not reach a stable level but will continually decline.

In this non-equilibrium situation the lifespan of cccDNA may be less than our inferred

26 days since the viral generation time will be greater than the lifespan of cccDNA (Fig

3 and methods).

Our model suggests cccDNA lifespan can be up to two times longer when few cells are

infected compared to when most cells are infected cells (see methods; compare Eqs 9

and 10). When few cells are infected there is less cell death due to cytolytic immune

responses, a lower rate of hepatocyte proliferation to maintain the number of

hepatocytes, and consequently reduced loss of cccDNA via mitosis of infected cells.

This is of more than theoretical interest, because when estimating how long it will take

to deplete the cccDNA reservoir on treatment, it is the lifespan of cccDNA when

relatively few cells are infected that is important since treatment is known to reduce

the cccDNA load. The maximum expected cccDNA lifespan, corresponding to HBeAg^{POS}

infection, few infected cells, and no cccDNA surviving mitosis, is 123 days (71-472

days; Fig 2, green line). Reports for duck hepatitis B virus (DHBV) show a high

proportion of cccDNA survives mitosis [18]. In contrast, for HBV recent experimental

[9,17] and modelling [12] results suggest that relatively few cccDNA molecules survive

mitosis, making this longer lifespan a reasonable expectation.

Fig 2. Probability distributions for cccDNA lifespan during different stages of HBV

infection. The distributions for cccDNA in stable HBeAg^{POS} and HBeAg^{NEG} chronic

infection are based on the neutral mutation rate and rate of neutral evolution (orange

and blue lines, respectively). If the cccDNA burden during HBeAg^{NEG} infection is not

stable, but gradually falling (i.e. the basic reproduction number, R_0, is less than one)

the lifespan will be slightly less than inferred here. The upper estimate reflects the

maximum likely cccDNA lifespan when few cells are infected, based on the neutral

rate of evolution during HBeAg^{POS} infection and assuming no cccDNA survives mitosis

(q=0; green line).

Dynamics of the mathematical model

To demonstrate the behaviour of our model we present examples of the dynamics

when no cccDNA survives mitosis (q=0, Fig 3; see S1 Fig for model dynamics when q=1).

We used parameters that are compatible with our estimated cccDNA generation times

(61 days during HBeAg[POS] infection and 26 days during HBeAg[NEG] infection). Since

hepatocytes are long-lived we defined the natural death rate as $d=0.002$ per

hepatocyte per day throughout and, for simplicity, we set $c=0$ under the assumption

that cytolytic responses have greater antiviral activity than non-cytolytic responses.

We assume a neutral mutation rate $\mu=2\times10^{-5}$ s/s/c [20]. The model dynamics when

$q=1$ are similar to the case where $q=0$, apart from the lifespan of cccDNA in the early

stages of infection is predicted to be higher if q=1 (see below). A graphical

representation of the results is given in Fig 1C, and a summary of the parameters in

Table 2.

Table 2: Parameters used to describe the model dynamics[1,2]

| | Model 1 | | Model 2 | |
| | No cccDNA survives mitosis | | All cccDNA survives mitosis | |
	HBeAg[POS]	HBeAg[NEG]	HBeAg[POS]	HBeAg[NEG]
q	0	0	1	1
g	$g_E=61$	$g_E=26$ $^3g_{Y<<1}=26$ $^3g_{Y<<1}=26$	$g_E=61$	$g_E=26$ $^3g_{Y<<1}=26$ $^3g_{Y<<1}=26$
R_0	30.0	13.6 1.0 0.7	37.5	7.9 1.0 0.7
b	0.3	0.3 0.038 0.038	0.3	0.3 0.038 0.038

d	0.002	0.002	0.002	0.002
δ	0.006	0.018 0.034 0.050	0.014	0.036 0.036 0.052
c	0	0	0	0
μ	2×10^{-5}	2×10^{-5}	2×10^{-5}	2×10^{-5}

[1]All rates are given per day, and generation times are listed as days

[2]Where three values are given these refer to the alternative parameters used for

the different trajectories presented in Fig 3 and S1 Fig (top parameter, black line;

middle parameter, blue line; bottom parameter, orange line).

[3]Since R0<=1, a non-zero equilibrium is not reached.

HBeAg^{POS} infection

The replicative capacity of cccDNA, *b,* was chosen to be 0.3 per day so that the peak

number of cccDNA molecules in the liver is reached at approximately 3 months since

infection, in line with reported observations [28]. The per capita death rate of infected

cells due to cytolytic immune responses, δ, was determined assuming a cccDNA

generation time at equilibrium of 61 days, and solving Eq 9 for δ (giving δ=0.006 per

day if *q*=0; the associated R_0 is 30).

Under these assumptions, during the first few months of infection the cccDNA burden

(number of cccDNA divided by the maximum number of cccDNA) increases rapidly,

leading to a short viral generation time predicted by the model of 3.3 days (Eq 11, Fig

3, S1 Fig). A recent study estimated an eclipse period of approximately 3 days for a

newly infected cell to produce viral particles [2], so our estimated viral generation time

seems reasonable. This short generation time of cccDNA during early infection

contrasts with the long cccDNA lifespan (dots in Fig 3, S1 Fig; note the longer lifespan

predicted if $q=0$ compared to $q=1$). The neutral rate of evolution is also predicted to

be high during this early stage of infection due to the short generation time.

As infection progresses, the viral generation time increases due to fewer susceptible

target cells (Eq 5), in line with results in epidemiology [29], and this in turn reduces

the evolutionary rate (Eq 6). This dependency of evolutionary rate on epidemiological

dynamics has been noted in a previous simulation study on within-host viral infection

[30], but is generally an underappreciated factor influencing evolutionary rates. At

equilibrium, the estimated viral generation time and cccDNA lifespan are the same,

and it is this equivalency that enables us to determine these parameters from the

neutral rate of evolution, independent of the parameters of the model (see Methods).

Due to the long lifespan of infected hepatocytes, a high cccDNA burden is reached in

the model. This is in line with observations that most hepatocytes are infected at peak

infection [31].

HBeAg^{NEG} infection

We assumed the transition from HBeAg^{POS} to HBeAg^{NEG} occurs after an arbitrary

amount of time after HBeAg^{POS} equilibrium is reached and associates with a reduced

cccDNA generation time from 61 to 26 days. If this reduced generation time is not

accompanied by a decrease in replicative capacity, only a modest fall in the cccDNA

burden is predicted (Fig 3, blue line; $\delta=0.018$ per day and $b=0.3$ per day). However,

this is inconsistent with *in vivo* infections, where the number of cccDNA molecules and

extracellular HBV DNA levels (VL) typically decline by several orders of magnitude after

transition to HBeAg[NEG] infection [32,33]. If the cccDNA burden is low (Y<<1), then

replicative capacity, *b*, is estimated by the reciprocal of the generation time (*b=1/g*;

Eq 5). For a generation time of 26 days, this gives *b*=0.038 per day, leading to an

estimated 10-fold reduction in the ability of cccDNA to reproduce during HBeAg[NEG]

compared to HBeAg[POS] infection. In Fig 3, the orange line shows the model dynamics

given this decline in *b*, and when R_0=1 during HBeAg[NEG] infection (i.e. $\delta = 0.034$ per

day and *b*=0.038 per day). In this case, the cccDNA burden falls at a relatively modest

rate. Perhaps more likely is that R_0 < 1 and the number of cccDNA molecules continues

to decline. The green line shows the dynamics if R_0=0.7 ($\delta = 0.050$ per day). However,

even with this modest increase in δ, the number of cccDNA is predicted to fall rapidly.

The difficulty in explaining low but steady VL using standard within-host virus models,

and the sensitivity of VL to model parameters when R_0 is close to one, have been

acknowledged previously, particularly in relation to HIV-1 infections [34–36]. Possible

explanations for the low numbers of cccDNA during HBeAg[NEG] infection and low rates

of spontaneous cure include the existence of a small number of hepatocytes that are

susceptible to infection, resulting in low numbers of cccDNA molecules even if R_0 is

high [34], or the existence of a metapopulation-type partitioned structure in the liver,

which enables the cccDNA to persist when R_0 is low [36].

Fig 3. Population and evolutionary dynamics of cccDNA for the within-host model.
We assumed no cccDNA survives mitosis (q=0; see S1 Fig for the case where q=1). The
model was parameterised assuming the generation time, g, during chronic HBeAg^POS
infection is 61 days, and during chronic HBeAg^NEG infection is 26 days, in line with our
predictions for cccDNA generation time *in vivo*. The top panel shows cccDNA burden,
where 1 represents the maximum. The middle panel shows the viral generation time
(lines) and cccDNA lifespan during key stages of infection (dots, derived from Eqs 9
and 10). The bottom row shows the evolutionary rates. Black line: replicative capacity
during HBeAg^NEG infection remains the same as during HBeAg-postive infection (b_{eAg+}=
b_{eAg-}=0.3 per day). Blue line: replicative capacity falls to b_{eAg-}=0.038 per day during
HBeAg^NEG infection, and R_0=1. Orange line: replicative capacity falls to b_{eAg-}=0.038 per
day and R_0=0.7. See Table 1 for all other parameters.

Estimated time to eradicate cccDNA on treatment

When few cells are infected, the inferred cccDNA lifespan is 123 days during HBeAg[POS]

infection if q=0. Even with this longer estimate for cccDNA lifespan, if there are 10^{12}

cccDNA molecules at the start of treatment (see methods), we would expect the

reservoir to be depleted after less than ten years of treatment (Eq 13, Fig 4A).

Moreover, if treatment is initiated during HBeAg[NEG] CHB the time to eradicate cccDNA

is predicted to be even faster (only 1.5 years) with a lifespan of 26 days, and a lower

number of cccDNA molecules (2×10^9) in the liver at the start of treatment. However,

these predictions are in stark contrast to what is observed in the clinic, where a high

proportion of individuals remain infected after many years of continuous treatment

[37] and there is no appreciable difference in treatment mediated cure in HBeAg[NEG]

or HBeAg[POS] patients [8,38]. The discrepancy may arise due to our estimated cccDNA

lifespan being too short. An estimated lifespan of 236 days during HBeAg-postive CHB

still lies within our 95% confidence interval, and would give a time to eradication, and

hence sterilizing cure between 18 and 36 years (Eq 13). However, this does not explain

the long time to eradicate cccDNA during HBeAg[NEG] infection. Alternative explanations

include ongoing (albeit reduced) cccDNA amplification during NA treatment (b>0)

[8,39], or the presence of a long-lived subset of infected hepatocytes [17,40].

To evaluate these two scenarios, we modelled cccDNA dynamics in CHB patients on

treatment assuming different levels of viral replication (Fig 4B) or a subset of long-

lived cells (Fig 4C, S2 Fig). The dynamics of cccDNA are sensitive to the amount of

replication, making it unlikely that ongoing amplification alone explains the failure of

treatments to eliminate cccDNA. Apart from a narrow range of replicative capacities,

either a high and steady cccDNA burden, or relatively rapid cccDNA elimination, is

predicted on treatment. The existence of a long-lived population of infected

hepatocytes is more robust to differences in model parameters, with a gradual

increase in the time to eradicate cccDNA as the death rate of long-lived cells is

increased, making a long-lived population a more parsimonious explanation for the

slow decline in the HBV reservoir. However, since the decay dynamics of the reservoir

on treatment can be complex, and differ between individuals [39], a combination of

factors most likely explains the clinical observations.

Fig 4. Effect of NA treatment predicted by the model. A: Predicted time for cccDNA

to be eradicated in the absence of any cccDNA reproduction (b=0). B: cccDNA

dynamics whilst on treatment, assuming some residual reproduction. For all runs

d=0.002 per day, δ=0.006 per day, c=0, q=0. C: cccDNA dynamics on treatment,

assuming no residual reproduction (b=0) but 0.1% cccDNA is long-lived, for different

death rates of long-lived cells, d_r per day. For normal cells d=0.002 per day, δ=0.006

per day, c=0, q=0, and for long-lived cells δr=0, c_r=0, q=0. The maximum number of

cccDNA was assumed to be 10^{12}, and all model runs were started at equilibrium in the

absence of treatment (b=0.3 per day).

DISCUSSION

We provide a new model to estimate the HBV cccDNA lifespan based on reported mutation and within-host evolutionary rates [20,24,26]. The lifespan of cccDNA is an important component of the half-life of the cccDNA reservoir, which describes how the population of cccDNA molecules in an individual declines over time. We predict an average cccDNA lifespan of 61 days during HBeAg[POS] CHB compared to only 26 days in the HBeAg[NEG] phase of infection. Although estimates for the mutation and evolutionary rates for HBV are associated with high levels of uncertainty, our predicted lifespan is in agreement with *in vitro* studies showing a 40 day half-life of HBV cccDNA [2] and an estimated half-life of 33-57 days in woodchucks and ducks *in vivo* [41,42]. As far as we are aware, this is the first time cccDNA lifespan has been estimated during untreated infection. The lower lifespan during HBeAg[NEG] infection is consistent with a study in which VL data during therapy was fitted to a mathematical model, concluding that the turnover of infected cells is higher if therapy is initiated during HBeAg[NEG] infection [16], although our predictions for cccDNA persistence are longer [16] .

The shorter cccDNA lifespan during HBeAg[NEG] CHB may reflect host immune responses, with our model suggesting a doubling of the clearance rate compared to HBeAg[POS] infection. However, this increased clearance rate is predicted to have a modest effect on the total number of cccDNA molecules. As well as inferring the lifespan of cccDNA, we inferred cccDNA replicative capacity (a combined measure of intra and extra-cellular amplification). Our results predict an approximate ten-fold reduction in replicative capacity between HBeAg[POS] and HBeAg[NEG] phases of infection, which may

reflect host innate or adaptive immune responses suppressing viral production and/or

intra-cellular amplification. This can explain the lower cccDNA levels reported in

HBeAg[NEG] CHB [32,33], and is consistent with observations that the replicative capacity

of cccDNA in the HBeAg[NEG] phase of infection is reduced compared to HBeAg[POS]

infection [32]. This may reflect immune control at the level of the viral epigenome, but

without cell death [43].

In our modelling approach, we have assumed that viral dynamics are driven by host-

factors, in the absence of viral phenotypic evolution. The HBeAg[NEG] phase of infection

is often associated with an emergence of precore mutations that may affect HBV

replication and stability of cccDNA [44,45] . Viral phenotypic evolution is likely to have

an important role in viral dynamics, and we speculate that these viral phenotypic

changes could increase the rate of intra-cellular amplification, but at the expense of

killing the host cell, and therefore could represent a form of intra-host short-sighted

evolution [25].

Our estimates for cccDNA lifespan have implications for curative treatment strategies.

If NA therapy inhibits all cccDNA amplification, we would predict HBV to be cured after

1 to 10 years of continuous treatment. However, this is not observed in the clinic, with

only 1% of individuals clearing HBsAg each year [37]. Possible explanations for this

discrepancy are that NAs do not inhibit all intra- and extra-cellular amplification [8,39],

or the existence of long-lived infected cells [17,40]. Our model is consistent with the

presence of long-lived infected cells providing the most parsimonious explanation for

sustained infection on treatment. There is growing evidence that there is negligible

intra-cellular cccDNA amplification in human HBV infection [9], and since NA

treatment will inhibit the genesis of viral particles this will prevent extra-cellular

amplification. Furthermore, the dynamics of cccDNA clearance is sensitive to the

assumed amplification rates, and therefore if amplification alone explains the

dynamics we would expect to see a proportion of individuals clearing infection within

1-2 years of starting treatment. The presence of long-lived HBV infected cells has

parallels with the HIV reservoir, where long-lived latent-infected $CD4^+$ T cells prevent

cure [46]. Distinguishing between residual amplification and long-lived infected cells

will help define the expected impact of treatment strategies that prevent cccDNA

replication, compared to those directly targetting cccDNA. As HBV evolution will only

occur if there is cccDNA amplification, it may be possible to distinguish between these

two mechanisms by measuring the rate of cccDNA evolution whilst on treatment.

Our estimates of cccDNA persistence and amplification provide insights into

mechanisms underlying CHB and will inform our understanding of how spontaneous

or therapeutic clearance may be achieved. Given different infection profiles among

individuals, and limited datasets available for our model, the confidence intervals of

our estimations are wide. Our analysis exemplifies the power of modelling as a tool to

inform therapeutic interventions and highlights the need for genomic studies to

determine HBV evolutionary rates in CHB.

METHODS

To derive estimates of HBV cccDNA lifespan using the neutral mutation rate and the rate of evolution we developed a deterministic mathematical model describing the dynamics of cccDNA during the course of treatment naïve CHB. We used this model to derive expressions for viral generation time and neutral rate of evolution, both of which are predicted to change during the course of infection. Finally, we derived expressions for the lifespan of cccDNA during (i) stable CHB and (ii) when the proportion of infected cells is low, as would be expected in early stages of infection or in the first few months of NA treatment.

A within-host model of HBV dynamics

HBV cccDNA can replicate via intra-cellular and extra-cellular routes (Fig 1A), with a reported copy number between 1-50 molecules within a single hepatocyte nucleus [2,17,31,47–49] (the higher estimates tend to be for DHBV and lower estimates for human HBV [9]). Since cccDNA can be lost during mitosis, we modelled the number of cccDNA copies in the liver, rather than the number of infected cells. To do this, we implicitly assume that viral production is proportional to the number of cccDNA molecules. This is a reasonable assumption since VL has been reported to associate with increasing cccDNA copy numbers [32,50].

We describe the number of copies of cccDNA in the liver at time *t* since infection, *N(t)* as*:*

$$\frac{dN(t)}{dt} = \beta N(t)[K - N(t)] - (d + \delta + c)N(t) - \rho(t)(1 - q)N(t) \text{ (Eq1a)}$$

where the first term describes the increase in cccDNA due to intra- and extra-cellular

amplification. We assume that the rate of increase is density dependent, with a

maximum per capita growth rate β per day and a maximum possible number of

cccDNA, K. We assume K is constant since proliferation ensures the number of

hepatocytes in the liver remains stable during infection [15], and because evidence

suggests there is a maximum number of copies of cccDNA that can persist within each

hepatocyte, which is virally controlled [50–52]. In reality, the value of K is likely to fall

during infection, for example due to sections of the liver becoming cirrhotic and/or if

hepatocytes expressing HBsAg from integrated viral DNA have reduced susceptibility

of infection. However, since ours is a density dependent model, this will have only a

small effect on model dynamics if the change in K is much slower than viral dynamics,

as is expected. Moreover, our estimates for cccDNA lifespan (below) are based on

equilibrium values and are therefore independent of the value of K.

The second term describes the rate at which cccDNA is lost due to the natural death

of hepatocytes and the host immune response, under the assumption that cccDNA is

randomly distributed among infected hepatocytes. We assume that hepatocytes, and

therefore cccDNA, have a natural per capita death rate d per day. Infected

hepatocytes (and hence cccDNA) have an additional per capita death rate δ per day

due to cytolytic immune responses, and cccDNA is lost at per capita rate c per day due

to non-cytolytic immune responses.

The final term describes the loss of cccDNA due to cell proliferation. Uninfected and

infected hepatocytes are assumed to proliferate at the per capita rate $\rho(t)$ per day,

and hence cccDNA will be exposed to proliferation at rate, $\rho(t)$, with a probability q

that a cccDNA molecule will survive mitosis. Since the maximum possible number of

cccDNA, *K,* is assumed to be constant, proliferation and cell death are balanced,

hence:

$dK + \delta N(t) = \rho(t)K$ (Eq1b)

Here, the left-hand side represents the loss in carrying capacity due to the natural

death rate of all hepatocytes (including infected hepatocypes), and the additional

death rate incurred by infected hepatocytes as a direct result of infection. We are

making the assumption that cccDNA are randomly distributed among infected

hepatocytes, and that the natural death rate of hepatocytes is independent of

whether they are infected or not. Thus, for example, a 5% drop in the number

hepatoctyes results in a 5% drop in cccDNA carrying capacity. The right-hand side of

the equation represents consequential gain in cccDNA carrying capacity due to

proliferation that is needed for K to remain constant.

A complete expression for the dynamics of *N(t)* can be found by solving Eq 1b for $\rho(t)$

and substituting into Eq 1a. To simplify further, we consider the cccDNA burden in the

liver, $Y(t) = N(t)/K$, rather than the total number of cccDNA molecules, giving us:

$\frac{dY(t)}{dt} = b\,[1 - Y(t)]Y(t) - (d + \delta + c)Y(t) - (1 - q)[d + \delta Y(t)]Y(t)$

520   (Eq2)

where $b = \beta K$ is a rescaled measure of cccDNA replicative capacity. From this

equation we can calculate the basic reproductive rate of cccDNA, R_0, which is defined

as the number of new cccDNA molecules a single cccDNA molecule will produce in a

susceptible population of hepatocytes:

$R_0 = \frac{b}{d(2-q)+(\delta+c)}$ (Eq3)

If $R_0 < 1$, then the infection cannot be sustained in the long term. At equilibrium, the

cccDNA burden is given by:

$Y_E = Max\left[0, \frac{b - d(2-q) - (\delta+c)}{b + \delta(1-q)}\right]$ (Eq4)

which is equivalent to the cccDNA burden during stable chronic infection. Our model

considers the number of cccDNA molecules independent of their distribution within

cells. This is similar to the "single copy" modelling assumption used in [18], in which

only one cccDNA molecule can persist in a cell, and which was shown to produce

almost identical dynamics to one in which multiple copies of cccDNA are explicitly

modelled within infected cells [18].

An expression for the neutral rate of HBV evolution

In a large well-mixed viral population, and in the absence of selection, the rate of

evolution at time t is given by $S(t) = \mu/g(t)$, where μ is the (neutral) mutation rate,

measured per site per viral generation, and $g(t)$ is the generation time [53]. For our

within-host model of HBV infection, g is equivalent to the typical amount of time it

takes for one cccDNA molecule to replicate another molecule. This is similar to the

meaning of the generation time in demography and epidemiology [29,54,55]. From Eq

2, we can calculate the 'backwards' generation time as:

$g(t) = 1/[b(1 - Y(t))]$ $\hspace{4cm}$ (Eq5)

At time t since initial infection, the neutral substitution rate is therefore given by:

$S(t) = \frac{\mu}{g(t)} = \mu b[1 - Y(t)]$ $\hspace{3cm}$ (Eq6)

Since intra- and extra-cellular amplification involve an error-prone reverse

transcription step (in both cases cccDNA is the template for producing pgRNA, which

is then reversed transcribed to form rcDNA), we have assumed they have similar

mutation rates. Substituting Y_E into Eq 6, we can find an expression for the neutral

rate of evolution rate at equilibrium:

$S_E = \frac{\mu b[c + (2-q)(d+\delta)]}{b + \delta(1-q)}$ for $Y_E > 0$ $\hspace{2cm}$ (Eq7)

Lifespan of cccDNA during steady state infection

Lifespan of cccDNA during steady state infection

In our model, at equilibrium the generation time of HBV will be equal to the typical

cccDNA lifespan, L_E. At equilibrium the number of cccDNA molecules remains

constant, and therefore the rate at which cccDNA is produced is equal to the rate at

which cccDNA is lost due to infected cell death, non-cytolytic clearance of cccDNA, and

proliferation of infected cells. Since the reciprocal of the production rate is equal to

the generation time, and the reciprocal of the rate cccDNA is lost is the typical lifespan

of cccDNA, at equilibrium, viral generation time and cccDNA lifespan are identical

$(g_E = L_E)$. This relationship holds because of our assumption of constant death

rate and hence exponentially distributed lifetimes of cccDNA [29]; see [29,54] for

how this changes for different distributions.

Using the equivalence of g_E and L_E, the lifespan of cccDNA at equilibrium can be

determined from the mutation and neutral evolution rates by rearranging the first

part of Eq 6:

$L_E = \frac{\mu}{S_E}$ (Eq8)

Substituting the expression for S_E from Eq 7 into Eq 8, we can write an expression for

the lifespan of cccDNA at equilibrium based on the model parameters:

$L_E = \frac{b+\delta(1-q)}{b[c+(d+\delta)(2-q)]}$ for $Y_E > 0$ (Eq9)

The lifespan of cccDNA when few cells are infected

If infection increases the death rate of hepatocytes, then the level of proliferation (to

replace eliminated cells) will be larger the more cells are infected. Consequently, the

lifespan of cccDNA when few cells are infected (e.g. during early phases of infection

or during spontaneous clearance of infection, or after prolonged successful

suppressive treatment) may differ from the lifespan during HBeAg^{POS} or HBeAg^{NEG}

steady state infection. By setting *Y<<1* in equation 2, we can derive an expression for

cccDNA lifespan when the copy number or burden is low:

$$L_{Y \ll 1} \approx \frac{1}{c+d(2-q)+\delta} \qquad \text{(Eq10)}$$

Comparing the expressions for L_E and $L_{Y \ll 1}$, we can see that if all cccDNA survives

mitosis (*q=1*) or infection has a minimal effect on the death rate of infected cells (δ=0),

then cccDNA lifespan remains unchanged during infection (as long as *d* and *c* don't

change). However, if these conditions are not met, then the lifespan of cccDNA when

few cells are infected, $L_{Y \ll 1}$, can be up to double the lifespan during chronic stable

infection, L_E, for identical model parameters (e.g. when *q=c=d=0*, and *b>> δ*).

As we noted above, the cccDNA lifespan is only equivalent to the generation time at

equilibrium. Using equation 5, when few cells are infected, the generation time is

given by:

$$g_{Y \ll 1} \approx \frac{1}{b} \qquad \text{(Eq11)}$$

This has also been observed in the epidemiological literature [29]. Combining

equations 3, 10 and 11 we see that:

$$R_0 = \frac{L_{Y \ll 1}}{g_{Y \ll 1}}$$ (Eq12)

If $R_0 > 1$ and few cells are infected (i.e. the number of cccDNA is increasing) the life

expectancy of cccDNA will be greater than the viral generation time, whereas if $R_0 <$

1 the life expectancy will be less than the viral generation time. This might be the case

if, for example, increased immune responses associated with HBeAg[NEG] infection push

R_0 below one.

Estimating the generation time and lifespan of cccDNA from within-host

evolutionary rates.

During stable chronic infection, the lifespan of cccDNA, L_E, equals the viral generation

time, g_E, with $g_E = \mu / S_E$ (Eq 6). Although the mutation rate of HBV has not been

determined, for avian hepadnavirus it has been estimated at 2x10^{-5} s/s/c (in the range

0.8x10^{-5} to 4.5x10^{-5}; [20]). Since we are interested in the neutral rate of evolution, we

assume that a third of all mutations in non-overlapping reading frames are

synonymous, and that synonymous mutations are neutral or nearly neutral [56], giving

a neutral mutation rate of around 0.67x10^{-5} s/s/c (0.3x10^{-5} to 1.5x10^{-5}) in non-

overlapping reading frames. To incorporate the uncertainty associated with this

estimate, we assumed the probability of the true mutation rate is log-normally

distributed with mean 10$^{-5.2}$ and standard deviation 10$^{0.2}$.

Using longitudinal HBV sequence data, rates of evolution for non-overlapping regions

of the genome were generated using a relaxed clock method, inferring 16.1×10^{-8} (8.1

$\times 10^{-8}$, 25.5×10^{-8}) substitutions per site per day (s/s/day) for HBeAg[POS] and 38.9×10^{-8}

(27.2×10^{-8}, 51.5×10^{-8}) for HBeAg[NEG] chronic infection (the numbers in brackets give

the 5% and 95% highest posterior density (HPD) intervals; see Table 5 in [24]). In a

separate study, using data from [57], the synonymous rate of evolution in non-

overlapping genomic regions was estimated as half of the overall rate of evolution [26].

Assuming synonymous mutations are neutral, and that the ratio of synonymous to

nonsynonymous evolutionary rates is constant during infection, we therefore take the

neutral within-host rates of evolution during the HBeAg[POS] and HBeAg[NEG] phases of

infection to be half the rates of evolution reported in [24] for non-overlapping reading

frames. This gives a neutral rate of evolution of 8.0×10^{-8} (4.0×10^{-8}, 12.7×10^{-8}) s/s/day

during the HBeAg[POS] phase, and 19.5×10^{-8} (13.6×10^{-8}, 25.8×10^{-8}) s/n/day during the

HBeAg[NEG] phase. We assumed the probability distributions of these rates are normally

distributed, with the standard deviation calculated using the difference between the

estimated rate and the 5% HPD.

We randomly sampled from each of the probability distribution functions (PDFs) for

the mutation rate and substitution rates and used these values to calculate the

generation time of cccDNA during HBeAg[POS] and HBeAg[NEG] CHB. This was repeated

100,000 times, from which the probability distributions for cccDNA generation time

during HBeAg[POS] and HBeAg[NEG] chronic infection were estimated using the built in

SmoothKernelDistribution function in *Mathematica* [58]. Assuming the number of

cccDNA rapidly reaches equilibrium during HBeAg^{POS} and HBeAg^{NEG} infection, the virus

generation time will provide an approximation of the cccDNA lifespan during stable

chronic infection (Fig 3).

Time to cccDNA eradication on treatment

Apart from when treatment is first initiated, the number of infected cells on treatment

will be relatively low. Assuming eradication in our model is achieved when fewer than

one cccDNA molecule persists, and there is no cccDNA replication whilst on treatment,

the time to eradication can be approximated by:

$t_{erad} \approx L_{Y \ll 1} \, Ln[N_{init}]$ (Eq13)

where N_{init} is the number of cccDNA when therapy is initiated and *Ln* is the natural

logarithm. To determine reasonable values for N_{init}, we multiplied the number of

hepatocytes in a human liver by the number of cccDNA per hepatocyte during

untreated infection. There are about 1.4×10^8 hepatocytes per gram of human liver [59],

and an adult human liver is around 1.5kg, giving approximately 2×10^{11} hepatocytes in

total. In a recent study, an average of 6.3 copies of cccDNA per hepatocyte were found

during chronic HBeAg^{POS} infection, and 0.01 per hepatocyte during HBeAg^{NEG} infection

[32], which gives a total of approximately 1×10^{12} copies of cccDNA during HBeAg^{POS}

infection and 2×10^9 copies of cccDNA during HBeAg^{NEG} infection.

Model assuming a subset of long-lived hepatocytes

To model cccDNA dynamics in the presence of long-lived hepatocytes, we assume that

a constant proportion, α, of hepatocytes are long-lived, and the rest 'standard-lived',

with death of each cell type compensated for by proliferation of that same type. For

simplicity, we also assume there is no intra-cellular amplification, and with infection

occurring at the same per capita rate in standard- and long-lived uninfected cells.

Assuming the cccDNA carrying capacity of standard-lived cells is $(1 - \alpha)K$, and of

long-lived cells is αK, the numbers of cccDNA in standard-lived hepatocytes, *N*, and in

long-lived hepatocytes, *L*, are given by:

$\frac{dN(t)}{dt} = \beta[N(t) + L(t)] \left[\frac{(1-\alpha)K - N(t)}{(1-\alpha)K} \right] - (d + \delta + c)N(t) - \rho_N(t)(1 - q)N(t)$

(Eq14a)

$\frac{dL(t)}{dt} = \beta[N(t) + L(t)] \left[\frac{\alpha K - L(t)}{\alpha K} \right] - (d_L + \delta_L + c_L)L(t) - \rho_L(t)(1 - q)L(t)$ (Eq14b)

where d_L, δ_L and c_L represent the per capita natural death rates, cytoloytic death rate

and clearance rates of cccDNA in long-lived cells, and ρ_N and ρ_L the per capita

proliferation rates of standard- and long-lived cells. Since deaths of standard (or long-

lived) cells are balanced by proliferation of standard (or long-lived) cells, we have the

relationships:

$\rho_N(t)(1 - \alpha)K = d(1 - \alpha)K + \delta N(t)$ (Eq14c)

$\rho_L(t)\alpha K = d_L \alpha K + \delta_L L(t)$ (Eq14d)

As before, we can substitute expressions for $\rho_N(t)$ and $\rho_L(t)$ found from solving Eqs

14c,d, into Eqs 14a,b, convert numbers into proportions, and simplify, to give

expressions for the burden of cccDNA in standard-lived cells, *Y(t),* and in long-lived

cells, *Z(t):*

$\frac{dY(t)}{dt} = b\left[1 - \frac{Y(t)}{1-\alpha}\right][Y(t) + Z(t)] - (d + \delta + c)Y(t) - (1-q)\left[d + \frac{\delta Y(t)}{1-\alpha}\right]Y(t)$

(Eq15a)

$\frac{dZ(t)}{dt} = b\left[1 - \frac{Z(t)}{\alpha}\right][Y(t) + Z(t)] - (d_L + \delta_L + c_L)Z(t) - (1-q)\left[d + \frac{\delta_L Z(t)}{\alpha}\right]Z(t)$

(Eq15b)

ACKNOWLEDGEMENTS

Thank you to Fabian Zoulim and Helen Fryer for their helpful comments on earlier

versions of this work. KAL and LP are supported by The Wellcome Trust and the

Royal Society grant numbers, 107652/Z/15/Z and 202562/Z/16/Z

JAM is supported by EU 2020 Research and Innovation Programme Consortia HEP-CAR

under grant agreement No.667273, MRC MR/R022011/1 and The Wellcome Trust IA

200838/Z/16/Z. PM is supported by The Wellcome Trust, grant number

110110/Z/15/Z.

SUPPORTING FIGURES

S1 Fig. Population and evolutionary dynamics of cccDNA for the within-host model

assuming all cccDNA survives mitosis (q=1). The model was parameterised assuming

the generation time, g, during chronic HBeAg^{POS} infection is 61 days, and during

chronic HBeAg^{NEG} infection is 26 days, in line with our predictions for cccDNA

generation time *in vivo*. The top panel shows the cccDNA burden, where 1 represents

the maximum possible burden. The middle panel shows the viral generation time

(lines) and cccDNA lifespan during key stages of infection (dots, derived from Eqs 9

and 10). The bottom row shows the evolutionary rates. Black line: replicative capacity

during HBeAg^{NEG} infection remains the same as during HBeAg-postive infection (b_{eAg+}=

b_{eAg-}=0.3 per day). Blue line: replicative capacity falls to b_{eAg-}=0.038 per day during

HBeAg^{NEG} infection, and R_0=1. Orange line: replicative capacity falls to b_{eAg-}=0.038 per

day and R_0=0.7. See Table 1 for all other parameters.

S2 Fig. Effect of NA treatment predicted by the model assuming all cccDNA survives

mitosis (q=1). A: cccDNA dynamics whilst on treatment, assuming some residual

reproduction. For all cells d=0.002 per day, δ=0.014 per day, c=0, q=1. B: cccDNA

dynamics on treatment, assuming no residual reproduction (b=0) but 0.1% cccDNA is

long-lived, for different death rates of long-lived cells, d_r per day. For normal cells

d=0.002, δ=0.014, c=0, q=1, and for long-lived cells δ_r=0, c_r=0, q=0. The maximum

number of cccDNA was assumed to be 10^{12}, and all model runs were started at

equilibrium in the absence of treatment (b=0.3).

REFERENCES

1. WHO. Global hepatitis report. 2017.

2. Ko C, Chakraborty A, Chou W, Mckeating JA, Ryu W, Protzer U. Hepatitis B

virus genome recycling and de novo secondary infection events maintain

stable cccDNA levels. J Hepatol. European Association for the Study of the

Liver; 2018;69: 1231–1241. doi:10.1016/j.jhep.2018.08.012

3. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B

virus. J Hepatol. European Association for the Study of the Liver; 2010;52:

282–284. doi:10.1016/j.jhep.2009.10.031

4. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA – The holy grail to

hepatitis B cure. J Hepatol. European Association for the Study of the Liver;

2016;64: S41–S48. doi:10.1016/j.jhep.2016.02.009

5. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure

of chronic hepatitis B. Gut. 2015;64: 1972–1984. doi:10.1136/gutjnl-2015-

309809

6. Revill PA, Chisari F V, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global

scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:

545–548. doi:10.1016/S2468-1253(19)30119-0

7. Laporte V, Charlesworth B. Effective population size and population

subdivision in demographically structured populations. Genetics. 2002;162:

501–19.

8. Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, et al.

Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under

tenofovir in HIV-HBV co-infected patients. J Hepatol. European Association for

the Study of the Liver; 2016;65: 683–691. doi:10.1016/j.jhep.2016.05.014

9.   Tu T, Urban S. Virus entry and its inhibition to prevent and treat hepatitis B

and hepatitis D virus infections. Curr Opin Virol. Elsevier B.V.; 2018;30: 68–79.

doi:10.1016/j.coviro.2018.04.004

10.   Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther.

2010;15: 3–14. doi:10.3851/IMP1619

11.   Murray JM, Goyal A. In silico single cell dynamics of hepatitis B virus infection

and clearance. J Theor Biol. Elsevier; 2015;366: 91–102.

doi:10.1016/j.jtbi.2014.11.020

12.   Goyal A, Ribeiro RM, Perelson AS. The Role of Infected Cell Proliferation in the

Clearance of Acute HBV Infection in Humans. Viruses. 2017; 350.

doi:10.3390/v9110350

13.   EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B

virus infection. J Hepatol. 2017;67: 370–398. doi:10.5152/tjg.2017.20817

14.   Downs LO, Vawda S, Bester PA, Mcnaughton AL, Lythgoe KA, Wang T, et al.

Bimodal distribution and set point HBV DNA viral loads in chronic infection :

retrospective analysis of cohorts from the UK and South Africa [version 1 ;

peer review : awaiting peer review]. 2020; 1–6.

15.   Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV DNA Integration

and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered

Immune Tolerant. Gastroenterology. Elsevier, Inc; 2016;151: 986-998.e4.

doi:10.1053/j.gastro.2016.07.012

16.   Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS, et

al. Hepatitis B Virus Kinetics under Antiviral Therapy Sheds Light on

Differences in Hepatitis B e Antigen Positive and Negative Infections. J Infect

Dis. 2010;202: 1309–1318. doi:10.1086/656528

17.   Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, et al. Proliferation of

primary human hepatocytes and prevention of hepatitis B virus reinfection

efficiently deplete nuclear cccDNA in vivo. Hepatology. 2018;67: 542–552.

doi:10.1136/gutjnl-2016-312162

18.   Reaiche-Miller GY, Thorpe M, Low HC, Qiao Q, Scougall CA, Mason WS, et al.

Duck hepatitis B virus covalently closed circular DNA appears to survive

hepatocyte mitosis in the growing liver. Virology. 2013;446: 357–364.

doi:10.1016/j.virol.2013.08.014

19.   McNaughton AL, Arienzo VD, Ansari MA, Lumley SF, Littlejohn M, Revill P, et

al. Insights From deep sequencing of the HBV genome - Unique, tiny, and

misunderstood. Gastroenterology. Elsevier, Inc; 2019;156: 384–399.

doi:10.1053/j.gastro.2018.07.058

20.   Pult I, Abbott N, Zhang YY, Summers J. Frequency of spontaneous mutations in

an avian hepadnavirus infection. J Virol. 2001;75: 9623–32.

doi:10.1128/JVI.75.20.9623-9632.2001

21.   Pereira-Gómez M, Bou JV, Andreu I, Sanjuán R. Lamivudine/Adefovir

treatment increases the rate of spontaneous mutation of hepatitis B Virus in

patients. PLoS One. 2016;11: 1–12. doi:10.1371/journal.pone.0163363

22.   Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates.

J Virol. 2010;84: 9733–48. doi:10.1128/JVI.00694-10

23.   Pybus OG, Belshaw R, Sanjuan R. Viral mutation and substitution: Units and

levels. Curr Opin Virol. 2011;1: 430–435. doi:10.1016/j.coviro.2011.08.004

24.   Harrison A, Lemey P, Hurles M, Moyes C, Horn S, Pryor J, et al. Genomic

analysis of hepatitis B virus reveals antigen state and genotype as sources of

evolutionary rate variation. Viruses. 2011;3: 83–101. doi:10.3390/v3020083

25.   Lythgoe KA, Gardner A, Pybus OG, Grove J. Short-Sighted Virus Evolution and a

Germline Hypothesis for Chronic Viral Infections. Trends Microbiol. Elsevier

Ltd; 2017;25: 336–348.

26.   Vrancken B, Suchard MA, Lemey P. Accurate quantification of within- and

between-host HBV evolutionary rates requires explicit transmission chain

modelling. Virus Evol. 2017;3: 1–9. doi:10.1093/ve/vex028

27.   Lanfear R, Kokko H, Eyre-walker A. Population size and the rate of evolution.

Trends Ecol Evol. Elsevier Ltd; 2014;29: 33–41. doi:10.1016/j.tree.2013.09.009

28.   Whalley BSA, Murray JM, Brown D, Webster GJM, Emery VC, Dusheiko GM, et

al. Kinetics of Acute Hepatitis B Virus Infection in Humans. J Exp Med.

2001;193: 847–854.

29.   Scalia G, Svensson Å, Asikainen T, Giesecke J. Mathematical Biosciences Some

model based considerations on observing generation times for communicable

diseases. 2010;223: 24–31. doi:10.1016/j.mbs.2009.10.004

30.   Scholle SO, Ypma RJF, Lloyd AL, Koelle K. Viral substitution rate variation can

arise from the interplay between within-host and epidemiological dynamics.

Am Nat. 2013;182: 494–513. doi:10.1086/672000

31.   Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck

hepatitis virus infections: very rapid recovery after a prolonged viremia and

infection of virtually every hepatocyte. J Virol. 1994;68: 5792–803.

32.   Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum

hepatitis B core-related antigen (HBcrAg) correlates with covalently closed

circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol.

European Association for the Study of the Liver; 2019;70: 615–625.

doi:10.1016/j.jhep.2018.11.030

33. Downs LO, Vawda S, Bester PA, Lythgoe KA, Wang T, McNaughton AL, et al.

Bimodal distribution and set point HBV DNA viral loads in chronic infection :

retrospective analysis of cohorts from the UK and South Africa. medRxiv.

2020; doi:http://dx.doi.org/10.1101/2020.01.08.20016972

34. Bonhoeffer S, Funk GA, Gunthard HF, Fischer M, Muller V. Glancing behind

virus load variation in HIV-1 infection. Trends Microbiol. 2003;11: 499–504.

doi:10.1016/j.tim.2003.09.002

35. Müller V, Marée AFM, De Boer RJ. Small variations in multiple parameters

account for wide variations in HIV-1 set-points: a novel modelling approach.

Proc R Soc B. 2001;268: 235–42. doi:10.1098/rspb.2000.1358

36. Lythgoe KA, Pellis L, Fraser C. Large Variations in HIV-1 Viral Load Explained by

Shifting-Mosaic Metapopulation Dynamics. PLoS Biol. 2016; 1002567.

doi:10.1371/journal.pbio.1002567

37. Downs LO, Smith DA, Lumley SF, Patel M, McNaughton AL, Mokaya J, et al.

Electronic health informatics data to describe clearance dynamics of hepatitis

B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus

infection. MBio. 2019;10: 1–15. doi:10.1128/mBio.00699-19

38. Wong DKH, Seto WK, Fung J, Ip P, Huang FY, Lai CL, et al. Reduction of

hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide

analogues of different potency. Clin Gastroenterol Hepatol. 2013;11: 1004-

1010.e1. doi:10.1016/j.cgh.2013.01.026

39.   Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles

of hepatitis B virus during antiviral therapy. Hepatology. 2009;49: 32–38.

doi:10.1002/hep.22586

40.   De Crignis E, Carofiglio F, Moulos P, Verstegen MMA, Romal S, Khalid MM, et

al. Human liver organoids; a patient-derived primary model for HBV infection

and related hepatocellular carcinoma. bioRxiv. 2019; 568147.

doi:10.1101/568147

41.   Addison WR, Walters K-A, Wong WWS, Wilson JS, Madej D, Jewell LD, et al.

Half-life of the duck hepatitis B virus covalently closed circular DNA pool in

vivo following inhibition of viral replication. J Virol. 2002;76: 6356–6363.

doi:10.1128/JVI.76.12.6356-6363.2002

42.   Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of

Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis. J

Virol. 2001;75: 311–322. doi:10.1128/jvi.75.1.311-322.2001

43.   Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al.

Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low

Viremia in Most HBeAg-Negative Patients. Gastroenterology. 2007;133: 843–

852. doi:10.1053/j.gastro.2007.06.057

44.   Mason WS, Litwin S, Jilbert AR. Immune selection during chronic hepadnavirus

infection. Hepatol Int. 2008;2: 3–16. doi:10.1007/s12072-007-9024-3

45.   Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis

B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

Gastroenterology. 2003;124: 327–334. doi:10.1053/gast.2003.50053

46.   Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-

896   level viremia persists for at least 7 years in patients on suppressive

897   antiretroviral therapy. Proc Natl Acad Sci United States Am. 2008;105: 3879–

898   3884.

899   47.   Zhang Y, Zhang B, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of

900   covalently closed circular DNA copy numbers in a hepadnavirus-infected liver.

901   Proc Natl Acad Sci United States Am. 2003;100: 12372–12377.

902   48.   Li M, Sohn JA, Seeger C. Distribution of Hepatitis B Virus Nuclear DNA. J Virol.

903   2017;92: 1–13. doi:10.1128/jvi.01391-17

904   49.   Jilbert AR, Wu TT, England JM, Hall PM, Carp NZ, O'Connell AP, et al. Rapid

905   resolution of duck hepatitis B virus infections occurs after massive

906   hepatocellular involvement. J Virol. 1992;66: 1377–1388.

907   50.   Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with

908   enhanced replication and cytopathicity in primary hepatocytes. J Virol.

909   1994;68: 5706–5713.

910   51.   Summers J, Smith PM, Horwich AL. Hepadnavirus Envelope Proteins Regulate

911   Covalently Closed Circular DNA Amplification. J Virol. 1990;64: 2819–2824.

912   52.   Summers J, Smith PM, Huang MJ, Yu MS. Morphogenetic and regulatory

913   effects of mutations in the envelope proteins of an avian hepadnavirus. J Virol.

914   1991;65: 1310–7.

915   53.   Kimura M. The Neutral Theory of Molecular Evolution. Cambridge: Cambridge

916   University Press; 1985.

917   54.   Svensson Å. A note on generation times in epidemic models ˚. Mathematic.

918   2007;208: 300–311. doi:10.1016/j.mbs.2006.10.010

919   55.   Nishiura H. Time variations in the generation time of an infectious disease:

920   Implications for sampling to appropriately quantify transmission potential.

921   Math Biosci Eng. 2010;7: 851–869. doi:10.3934/mbe.2010.7.851

922   56.   Cuevas JM, Domingo-Calap P, Sanjuán R. The Fitness Effects of Synonymous

923   Mutations in DNA and RNA Viruses. Mol Biol Evol. 2011;29: 17–20.

924   doi:10.1093/molbev/msr179

925   57.   Lin Y-Y, Liu C, Chien W-H, Wu L-L, Tao Y, Wu D, et al. New Insights into the

926   Evolutionary Rate of Hepatitis B Virus at Different Biological Scales. J Virol.

927   2015;89: 3512–3522. doi:10.1128/JVI.03131-14

928   58.   Mathematica Version 10.3. Champaign, Illinois: Wolfram Research, Inc; 2015.

929   59.   Sohlenius-Sternbeck AK. Determination of the hepatocellularity number for

930   human, dog, rabbit, rat and mouse livers from protein concentration

931   measurements. Toxicol Vitr. 2006;20: 1582–1586.

932   doi:10.1016/j.tiv.2006.06.003